Search

Your search keyword '"Duarte, Luisa F."' showing total 37 results
Start Over Author "Duarte, Luisa F."
37 results on '"Duarte, Luisa F."'

1. Asymptomatic herpes simplex virus brain infection elicits cellular senescence phenotypes in the central nervous system of mice suffering multiple sclerosis-like disease

Author

Duarte, Luisa F., Villalobos, Verónica, Farías, Mónica A., Rangel-Ramírez, Ma. Andreina, González-Madrid, Enrique, Navarro, Areli J., Carbone-Schellman, Javier, Domínguez, Angélica, Alvarez, Alejandra, Riedel, Claudia A., Bueno, Susan M., Kalergis, Alexis M., Cáceres, Mónica, and González, Pablo A.

Published
2024
Full Text
View/download PDF

3. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults

Author

Rojas, Álvaro, Navarrete, María Soledad, Del Río, Constanza, Del Pino, Dinely, Aguirre, Natalia, Salinas, Grecia, Vega, Franco, Salgado, Acsa, Quinteros, Thomas, Ortiz, Marlene, Puente, Marcela, Muñoz, Alma, Astudillo, Patricio, Le Corre, Nicole, Potin, Marcela, Catalán, Juan, Peralta, Melan, Zamanillo, Consuelo, Keller, Nicole, Fernández, Rocío, Aljaro, Sofía, López, Sofía, González, José Tomás, Weil, Tania, Opazo, Luz, Muñoz, Paula, Estay, Inés, Cantillana, Miguel, Carrera, Liliana, Masalleras, Matías, Guzmán, Paula, Aguirre, Francisca, Cortés, Aarón, Bátiz, Luis Federico, Pérez, Javiera, Apablaza, Karen, Yates, Lorena, Valdés, María de los Ángeles, Hurtado, Bernardita, Venteneul, Veronique, Astorga, Constanza, Muñoz-Venturelli, Paula, Vial, Pablo A., Schilling, Andrea, Pavez, Daniela, Pérez, Inia, Riviotta, Amy, González, Francisca, Urrutia, Francisca, Del Río, Alejandra, Asenjo, Claudia, Vargas, Bárbara, Castro, Francisca, Acuña, Alejandra, Guzmán, Javiera, Astudillo, Camila, Pérez, Carlos M., Espinoza, Pilar, Martínez, Andrea, Arancibia, Marcela, Romero, Harold, Bustamante, Cecilia, Pérez, María Loreto, Uribe, Natalia, Silva, Viviana, Morice, Bernardita, Pérez, Marco, González, Marcela, Jensen, Werner, Pasten, Claudia, Aguilera, M. Fernanda, Martínez, Nataly, Molina, Camila, Arrieta, Sebastián, López, Begoña, Ortiz, Claudia, Escobar, Macarena, Bustamante, Camila, Espinoza, Marcia, Pardo, Angela, Carrasco, Alison, Montes, Miguel, Saldías, Macarena, Gutiérrez, Natalia, Sánchez, Juliette, Fuentes, Daniela, Calvo, Yolanda, Cepeda, Mariela, Lemus, Rosario, Suárez, Muriel, Armijo, Mercedes, Monsalves, Shirley, Marucich, Constance, Cornejo, Cecilia, Acosta, Ángela, Prado, Xaviera, Yáñez, Francisca, Barroeta, Marisol, López, Claudia, Donato, Paulina, Lasso, Martin, Iturrieta, María, Giraldo, Juan, Gutiérrez, Francisco, Acuña, María, Cascone, Ada, Rojas, Raymundo, Sepúlveda, Camila, Contreras, Mario, Campisto, Yessica, González, Pablo, Quizhpi, Zoila, López, Mariella, Pizzeghello, Vania, Silva, Stephannie, Méndez, Constanza, Peñaloza, Hernán F., Schultz, Bárbara M., Piña-Iturbe, Alejandro, Ríos, Mariana, Moreno-Tapia, Daniela, Pereira-Sánchez, Patricia, Leighton, Diane, Orellana, Claudia, Covarrubias, Consuelo, Gálvez, Nicolás M.S., Soto, Jorge A., Duarte, Luisa F., Rivera-Pérez, Daniela, Vázquez, Yaneisi, Cabrera, Alex, Bustos, Sergio, Iturriaga, Carolina, Urzua, Marcela, Navarrete, María S., Fasce, Rodrigo A., Fernández, Jorge, Mora, Judith, Ramírez, Eugenio, Gaete-Argel, Aracelly, Acevedo, Mónica, Valiente-Echeverría, Fernando, Soto-Rifo, Ricardo, Weiskopf, Daniela, Grifoni, Alba, Sette, Alessandro, Zeng, Gang, Meng, Weining, González-Aramundiz, José V., González, Pablo A., Abarca, Katia, Melo-González, Felipe, Bueno, Susan M., and Kalergis, Alexis M.

Published
2023
Full Text
View/download PDF

4. On the informative value of community‐based indoor radon values in relation to lung cancer.

Author

Rosenberger, Albert, Bickeböller, Heike, Christiani, David C., Liu, Geoffrey, Schabath, Matthew B., Duarte, Luisa F., Le Marchand, Loic, Haiman, Christopher, Landi, Teresa, Consonni, Dario, Field, John K., Davies, Michael P. A., Albanes, Demetrios, Tardón, Adonina, Fernández‐Tardón, Guillermo, Rennert, Gad, Amos, Christopher I., and Hung, Rayjean J.

Subjects
SMALL cell lung cancer, LUNG cancer, SQUAMOUS cell carcinoma, RADON, RESIDENTIAL areas
Abstract

Background: Radon is a radioactive gas and a major risk factor for lung cancer (LC). Methods: We investigated the dose–response relationship between radon and LC risk in the International Lung Cancer Consortium with 8927 cases and 5562 controls from Europe, North America, and Israel, conducted between 1992 and 2016. Spatial indoor radon exposure in the residential area (sIR) obtained from national surveys was linked to the participants' residential geolocation. Parametric linear and spline functions were fitted within a logistic regression framework. Results: We observed a non‐linear spatial‐dose response relationship for sIR < 200 Bq/m3. The lowest risk was observed for areas of mean exposure of 58 Bq/m3 (95% CI: 56.1–59.2 Bq/m3). The relative risk of lung cancer increased to the same degree in areas averaging 25 Bq/m3 (OR = 1.31, 95% CI: 1.01–1.59) as in areas with a mean of 100 Bq/m3 (OR = 1.34, 95% CI: 1.20–1.45). The strongest association was observed for small cell lung cancer and the weakest for squamous cell carcinoma. A stronger association was also observed in men, but only at higher exposure levels. The non‐linear association is primarily observed among the younger population (age < 69 years), but not in the older population, which can potentially represent different biological radiation responses. Conclusions: The sIR is useful as proxy of individual radon exposure in epidemiological studies on lung cancer. The usual assumption of a linear, no‐threshold dose–response relationship, as can be made for individual radon exposures, may not be optimal for sIR values of less than 200 Bq/m3. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Contribution of viral and bacterial infections to senescence and immunosenescence

Author

Reyes, Antonia, primary, Ortiz, Gerardo, additional, Duarte, Luisa F., additional, Fernández, Christian, additional, Hernández-Armengol, Rosario, additional, Palacios, Pablo A., additional, Prado, Yolanda, additional, Andrade, Catalina A., additional, Rodriguez-Guilarte, Linmar, additional, Kalergis, Alexis M., additional, Simon, Felipe, additional, Carreño, Leandro J., additional, Riedel, Claudia A., additional, Cáceres, Mónica, additional, and González, Pablo A., additional

Published
2023
Full Text
View/download PDF

7. Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects

Author

Duarte, Luisa F, primary, Vázquez, Yaneisi, additional, Diethelm-Varela, Benjamín, additional, Pavez, Valentina, additional, Berríos-Rojas, Roslye, additional, Méndez, Constanza, additional, Riedel, Claudia A, additional, White, Jessica A, additional, Kalergis, Alexis M, additional, Bueno, Susan M, additional, and González, Pablo A, additional

Published
2023
Full Text
View/download PDF

8. Heme Oxygenase-1 Expression in Dendritic Cells Contributes to Protective Immunity against Herpes Simplex Virus Skin Infection

Author

Tognarelli, Eduardo I., primary, Duarte, Luisa F., additional, Farías, Mónica A., additional, Cancino, Felipe A., additional, Corrales, Nicolás, additional, Ibáñez, Francisco J., additional, Riedel, Claudia A., additional, Bueno, Susan M., additional, Kalergis, Alexis M., additional, and González, Pablo A., additional

Published
2023
Full Text
View/download PDF

9. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults

Author

Méndez, Constanza, primary, Peñaloza, Hernán F., additional, Schultz, Bárbara M., additional, Piña-Iturbe, Alejandro, additional, Ríos, Mariana, additional, Moreno-Tapia, Daniela, additional, Pereira-Sánchez, Patricia, additional, Leighton, Diane, additional, Orellana, Claudia, additional, Covarrubias, Consuelo, additional, Gálvez, Nicolás M.S., additional, Soto, Jorge A., additional, Duarte, Luisa F., additional, Rivera-Pérez, Daniela, additional, Vázquez, Yaneisi, additional, Cabrera, Alex, additional, Bustos, Sergio, additional, Iturriaga, Carolina, additional, Urzua, Marcela, additional, Navarrete, María S., additional, Rojas, Álvaro, additional, Fasce, Rodrigo A., additional, Fernández, Jorge, additional, Mora, Judith, additional, Ramírez, Eugenio, additional, Gaete-Argel, Aracelly, additional, Acevedo, Mónica, additional, Valiente-Echeverría, Fernando, additional, Soto-Rifo, Ricardo, additional, Weiskopf, Daniela, additional, Grifoni, Alba, additional, Sette, Alessandro, additional, Zeng, Gang, additional, Meng, Weining, additional, González-Aramundiz, José V., additional, González, Pablo A., additional, Abarca, Katia, additional, Melo-González, Felipe, additional, Bueno, Susan M., additional, Kalergis, Alexis M., additional, Navarrete, María Soledad, additional, Del Río, Constanza, additional, Del Pino, Dinely, additional, Aguirre, Natalia, additional, Salinas, Grecia, additional, Vega, Franco, additional, Salgado, Acsa, additional, Quinteros, Thomas, additional, Ortiz, Marlene, additional, Puente, Marcela, additional, Muñoz, Alma, additional, Astudillo, Patricio, additional, Le Corre, Nicole, additional, Potin, Marcela, additional, Catalán, Juan, additional, Peralta, Melan, additional, Zamanillo, Consuelo, additional, Keller, Nicole, additional, Fernández, Rocío, additional, Aljaro, Sofía, additional, López, Sofía, additional, González, José Tomás, additional, Weil, Tania, additional, Opazo, Luz, additional, Muñoz, Paula, additional, Estay, Inés, additional, Cantillana, Miguel, additional, Carrera, Liliana, additional, Masalleras, Matías, additional, Guzmán, Paula, additional, Aguirre, Francisca, additional, Cortés, Aarón, additional, Bátiz, Luis Federico, additional, Pérez, Javiera, additional, Apablaza, Karen, additional, Yates, Lorena, additional, Valdés, María de los Ángeles, additional, Hurtado, Bernardita, additional, Venteneul, Veronique, additional, Astorga, Constanza, additional, Muñoz-Venturelli, Paula, additional, Vial, Pablo A., additional, Schilling, Andrea, additional, Pavez, Daniela, additional, Pérez, Inia, additional, Riviotta, Amy, additional, González, Francisca, additional, Urrutia, Francisca, additional, Del Río, Alejandra, additional, Asenjo, Claudia, additional, Vargas, Bárbara, additional, Castro, Francisca, additional, Acuña, Alejandra, additional, Guzmán, Javiera, additional, Astudillo, Camila, additional, Pérez, Carlos M., additional, Espinoza, Pilar, additional, Martínez, Andrea, additional, Arancibia, Marcela, additional, Romero, Harold, additional, Bustamante, Cecilia, additional, Pérez, María Loreto, additional, Uribe, Natalia, additional, Silva, Viviana, additional, Morice, Bernardita, additional, Pérez, Marco, additional, González, Marcela, additional, Jensen, Werner, additional, Pasten, Claudia, additional, Aguilera, M. Fernanda, additional, Martínez, Nataly, additional, Molina, Camila, additional, Arrieta, Sebastián, additional, López, Begoña, additional, Ortiz, Claudia, additional, Escobar, Macarena, additional, Bustamante, Camila, additional, Espinoza, Marcia, additional, Pardo, Angela, additional, Carrasco, Alison, additional, Montes, Miguel, additional, Saldías, Macarena, additional, Gutiérrez, Natalia, additional, Sánchez, Juliette, additional, Fuentes, Daniela, additional, Calvo, Yolanda, additional, Cepeda, Mariela, additional, Lemus, Rosario, additional, Suárez, Muriel, additional, Armijo, Mercedes, additional, Monsalves, Shirley, additional, Marucich, Constance, additional, Cornejo, Cecilia, additional, Acosta, Ángela, additional, Prado, Xaviera, additional, Yáñez, Francisca, additional, Barroeta, Marisol, additional, López, Claudia, additional, Donato, Paulina, additional, Lasso, Martin, additional, Iturrieta, María, additional, Giraldo, Juan, additional, Gutiérrez, Francisco, additional, Acuña, María, additional, Cascone, Ada, additional, Rojas, Raymundo, additional, Sepúlveda, Camila, additional, Contreras, Mario, additional, Campisto, Yessica, additional, González, Pablo, additional, Quizhpi, Zoila, additional, López, Mariella, additional, Pizzeghello, Vania, additional, and Silva, Stephannie, additional

Published
2023
Full Text
View/download PDF

10. On the Non-Linearity of Radon-Induced Lung Cancer

Author

Rosenberger, Albert, primary, Bickeböller, Heike, additional, Christiani, David C., additional, Liu, Geoffrey, additional, Schabath, Matthew B., additional, Duarte, Luisa F., additional, Le Marchand, Loïc, additional, Haiman, Christopher, additional, Landi, Teresa, additional, Consonni, Dario, additional, Field, John K., additional, Davies, Michael P.A., additional, Albanes, Demetrios, additional, Tardón, Adonina, additional, Fernández-Tardón, Guillermo, additional, Rennert, Gad, additional, Rennert, Hedy, additional, Amos, Christopher I., additional, and Hung, Rayjean J., additional

Published
2023
Full Text
View/download PDF

12. On the non-linearity of radon-induced lung cancer

Author

Rosenberger, Albert, primary, Bickeböller, Heike, additional, Christiani, David C, additional, Liu, Geoffrey, additional, Schabath, Matthew B, additional, Duarte, Luisa F., additional, Marchand, Loic Le, additional, Haiman, Christopher, additional, Landi, Teresa, additional, Consonni, Dario, additional, Field, John K, additional, Davies, Michael P.A., additional, Albanes, Demetrios, additional, Tardon, Adonina, additional, Fernández-Tardón, Guillermo, additional, Rennert, Gad, additional, Rennert, Hedy, additional, Amos, Christopher I, additional, and Hung, Rayjean J, additional

Published
2022
Full Text
View/download PDF

14. Pharmacological Inhibition of IRE-1 Alpha Activity in Herpes Simplex Virus Type 1 and Type 2-Infected Dendritic Cells Enhances T Cell Activation

Author

Tognarelli, Eduardo I., primary, Retamal-Díaz, Angello, additional, Farías, Mónica A., additional, Duarte, Luisa F., additional, Palomino, Tomás F., additional, Ibañez, Francisco J., additional, Riedel, Claudia A., additional, Kalergis, Alexis M., additional, Bueno, Susan M., additional, and González, Pablo A., additional

Published
2022
Full Text
View/download PDF

15. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

Author

Melo-González, Felipe, primary, Soto, Jorge A., additional, González, Liliana A., additional, Fernández, Jorge, additional, Duarte, Luisa F., additional, Schultz, Bárbara M., additional, Gálvez, Nicolás M. S., additional, Pacheco, Gaspar A., additional, Ríos, Mariana, additional, Vázquez, Yaneisi, additional, Rivera-Pérez, Daniela, additional, Moreno-Tapia, Daniela, additional, Iturriaga, Carolina, additional, Vallejos, Omar P., additional, Berríos-Rojas, Roslye V., additional, Hoppe-Elsholz, Guillermo, additional, Urzúa, Marcela, additional, Bruneau, Nicole, additional, Fasce, Rodrigo A., additional, Mora, Judith, additional, Grifoni, Alba, additional, Sette, Alessandro, additional, Weiskopf, Daniela, additional, Zeng, Gang, additional, Meng, Weining, additional, González-Aramundiz, José V., additional, González, Pablo A., additional, Abarca, Katia, additional, Ramírez, Eugenio, additional, Kalergis, Alexis M., additional, and Bueno, Susan M., additional

Published
2021
Full Text
View/download PDF

16. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine

Author

Duarte, Luisa F., primary, Gálvez, Nicolás M. S., additional, Iturriaga, Carolina, additional, Melo-González, Felipe, additional, Soto, Jorge A., additional, Schultz, Bárbara M., additional, Urzúa, Marcela, additional, González, Liliana A., additional, Vázquez, Yaneisi, additional, Ríos, Mariana, additional, Berríos-Rojas, Roslye V., additional, Rivera-Pérez, Daniela, additional, Moreno-Tapia, Daniela, additional, Pacheco, Gaspar A., additional, Vallejos, Omar P., additional, Hoppe-Elsholz, Guillermo, additional, Navarrete, María S., additional, Rojas, Álvaro, additional, Fasce, Rodrigo A., additional, Fernández, Jorge, additional, Mora, Judith, additional, Ramírez, Eugenio, additional, Zeng, Gang, additional, Meng, Weining, additional, González-Aramundiz, José V., additional, González, Pablo A., additional, Abarca, Katia, additional, Bueno, Susan M., additional, and Kalergis, Alexis M., additional

Published
2021
Full Text
View/download PDF

17. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Author

Bueno, Susan M, primary, Abarca, Katia, additional, González, Pablo A, additional, Gálvez, Nicolás M S, additional, Soto, Jorge A, additional, Duarte, Luisa F, additional, Schultz, Bárbara M, additional, Pacheco, Gaspar A, additional, González, Liliana A, additional, Vázquez, Yaneisi, additional, Ríos, Mariana, additional, Melo-González, Felipe, additional, Rivera-Pérez, Daniela, additional, Iturriaga, Carolina, additional, Urzúa, Marcela, additional, Domínguez, Angélica, additional, Andrade, Catalina A, additional, Berríos-Rojas, Roslye V, additional, Canedo-Marroquín, Gisela, additional, Covián, Camila, additional, Moreno-Tapia, Daniela, additional, Saavedra, Farides, additional, Vallejos, Omar P, additional, Donato, Paulina, additional, Espinoza, Pilar, additional, Fuentes, Daniela, additional, González, Marcela, additional, Guzmán, Paula, additional, Muñoz Venturelli, Paula, additional, Pérez, Carlos M, additional, Potin, Marcela, additional, Rojas, Álvaro, additional, Fasce, Rodrigo A, additional, Fernández, Jorge, additional, Mora, Judith, additional, Ramírez, Eugenio, additional, Gaete-Argel, Aracelly, additional, Oyarzún-Arrau, Aarón, additional, Valiente-Echeverría, Fernando, additional, Soto-Rifo, Ricardo, additional, Weiskopf, Daniela, additional, Sette, Alessandro, additional, Zeng, Gang, additional, Meng, Weining, additional, González-Aramundiz, José V, additional, and Kalergis, Alexis M, additional

Published
2021
Full Text
View/download PDF

19. IL-10-Dependent Amelioration of Chronic Inflammatory Disease by Microdose Subcutaneous Delivery of a Prototypic Immunoregulatory Small Molecule

Author

Tabares-Guevara, Jorge H., primary, Jaramillo, Julio C., additional, Ospina-Quintero, Laura, additional, Piedrahíta-Ochoa, Christian A., additional, García-Valencia, Natalia, additional, Bautista-Erazo, David E., additional, Caro-Gómez, Erika, additional, Covián, Camila, additional, Retamal-Díaz, Angello, additional, Duarte, Luisa F., additional, González, Pablo A., additional, Bueno, Susan M., additional, Riedel, Claudia A., additional, Kalergis, Alexis M., additional, and Ramírez-Pineda, José R., additional

Published
2021
Full Text
View/download PDF

21. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.

Author

Bueno, Susan M, Abarca, Katia, González, Pablo A, Gálvez, Nicolás M S, Soto, Jorge A, Duarte, Luisa F, Schultz, Bárbara M, Pacheco, Gaspar A, González, Liliana A, Vázquez, Yaneisi, Ríos, Mariana, Melo-González, Felipe, Rivera-Pérez, Daniela, Iturriaga, Carolina, Urzúa, Marcela, Domínguez, Angélica, Andrade, Catalina A, Berríos-Rojas, Roslye V, Canedo-Marroquín, Gisela, and Covián, Camila

Subjects
BLOOD testing, COVID-19, INJECTIONS, PAIN, IMMUNOGLOBULINS, COVID-19 vaccines, BLOOD collection, SEROCONVERSION, ANTIBODY formation, INTERFERONS, RANDOMIZED controlled trials, T cells, PATIENT safety
Abstract

Background The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports safety and immunogenicity results obtained for healthy Chilean adults aged ≥18 years in a phase 3 clinical trial. Methods Volunteers randomly received 2 doses of CoronaVac or placebo, separated by 2 weeks. A total of 434 volunteers were enrolled, 397 aged 18–59 years and 37 aged ≥60 years. Solicited and unsolicited adverse reactions were registered from all volunteers. Blood samples were obtained from a subset of volunteers and analyzed for humoral and cellular measures of immunogenicity. Results The primary adverse reaction in the 434 volunteers was pain at the injection site, with a higher incidence in the vaccine than in the placebo arm. Adverse reactions observed were mostly mild and local. No severe adverse events were reported. The humoral evaluation was performed on 81 volunteers. Seroconversion rates for specific anti-S1-receptor binding domain (RBD) immunoglobulin G (IgG) were 82.22% and 84.44% in the 18–59 year age group and 62.69% and 70.37% in the ≥60 year age group, 2 and 4 weeks after the second dose, respectively. A significant increase in circulating neutralizing antibodies was detected 2 and 4 weeks after the second dose. The cellular evaluation was performed on 47 volunteers. We detected a significant induction of T-cell responses characterized by the secretion of interferon-γ (IFN-γ) upon stimulation with Mega Pools of peptides from SARS-CoV-2. Conclusions Immunization with CoronaVac in a 0–14 schedule in Chilean adults aged ≥18 years is safe, induces anti-S1-RBD IgG with neutralizing capacity, activates T cells, and promotes the secretion of IFN-γ upon stimulation with SARS-CoV-2 antigens. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial

Author

Bueno, Susan M, primary, Abarca, Katia, additional, González, Pablo A, additional, Gálvez, Nicolás MS, additional, Soto, Jorge A, additional, Duarte, Luisa F, additional, Schultz, Bárbara M, additional, Pacheco, Gaspar A, additional, González, Liliana A, additional, Vázquez, Yaneisi, additional, Ríos, Mariana, additional, Melo-González, Felipe, additional, Rivera-Pérez, Daniela, additional, Iturriaga, Carolina, additional, Urzúa, Marcela, additional, Dominguez, Angélica, additional, Andrade, Catalina A, additional, Berrios, Roslye V, additional, Canedo-Marroquín, Gisela, additional, Covián, Camila, additional, Moreno-Tapia, Daniela, additional, Saavedra, Farides, additional, Vallejos, Omar P, additional, Donato, Paulina, additional, Espinoza, Pilar, additional, Fuentes, Daniela, additional, González, Marcela, additional, Guzmán, Paula, additional, Muñoz-Venturelli, Paula, additional, Pérez, Carlos M, additional, Potin, Marcela, additional, Rojas, Alvaro, additional, Fasce, Rodrigo, additional, Fernández, Jorge, additional, Mora, Judith, additional, Ramírez, Eugenio, additional, Gaete-Argel, Aracelly, additional, Oyarzún-Arrau, Aarón, additional, Valiente-Echeverría, Fernando, additional, Soto-Rifo, Ricardo, additional, Weiskopf, Daniela, additional, Sette, Alessandro, additional, Zeng, Gang, additional, Meng, Weining, additional, González-Aramundiz, José V, additional, and Kalergis, Alexis M, additional

Published
2021
Full Text
View/download PDF

24. Asymptomatic Herpes Simplex Virus Type 1 Infection Causes an Earlier Onset and More Severe Experimental Autoimmune Encephalomyelitis

Author

Duarte, Luisa F., primary, Altamirano-Lagos, María J., additional, Tabares-Guevara, Jorge H., additional, Opazo, Ma. Cecilia, additional, Díaz, Máximo, additional, Navarrete, Romina, additional, Muza, Catalina, additional, Vallejos, Omar P., additional, Riedel, Claudia A., additional, Bueno, Susan M., additional, Kalergis, Alexis M., additional, and González, Pablo A., additional

Published
2021
Full Text
View/download PDF

28. A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses

Author

Boyle, Theresa A., primary, Quinn, Gwendolyn P., additional, Schabath, Matthew B., additional, Muñoz‐Antonia, Teresita, additional, Saller, James J., additional, Duarte, Luisa F., additional, Hair, Laura S., additional, Teer, Jamie K., additional, Chiang, Derek Y., additional, Leary, Rebecca, additional, Wong, Connie C., additional, Savchenko, Alexander, additional, Singh, Angad P., additional, Charette, LaSalette, additional, Mendell, Kate, additional, Gorgun, Gullu, additional, Antonia, Scott J., additional, Chiappori, Alberto A., additional, Creelan, Benjamin C., additional, Gray, Jhanelle E., additional, and Haura, Eric B., additional

Published
2019
Full Text
View/download PDF

31. A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses.

Author

Boyle, Theresa A., Quinn, Gwendolyn P., Schabath, Matthew B., Muñoz‐Antonia, Teresita, Saller, James J., Duarte, Luisa F., Hair, Laura S., Teer, Jamie K., Chiang, Derek Y., Leary, Rebecca, Wong, Connie C., Savchenko, Alexander, Singh, Angad P., Charette, LaSalette, Mendell, Kate, Gorgun, Gullu, Antonia, Scott J., Chiappori, Alberto A., Creelan, Benjamin C., and Gray, Jhanelle E.

Subjects
LUNG cancer, ORGAN donation, ANAPLASTIC lymphoma kinase, ANAPLASTIC thyroid cancer, MOLECULAR evolution, RNA analysis, POSTMORTEM changes
Abstract

Background: For the advancement of cancer research, the collection of tissue specimens from drug‐resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post‐therapy specimens are not routinely collected due to the risks of collection, limiting the study of targeted therapy resistance mechanisms. Posthumous rapid tissue donation (RTD) is an expedient collection process that provides an opportunity to understand treatment‐resistant lung cancers. Methods: Consent to participate in the thoracic RTD protocol was obtained during patient care. When death occurred, tumor and paired non‐tumor, cytology, and blood specimens were collected within 48 hours and preserved as formalin‐fixed and frozen specimens. Tissue sections were evaluated with hematoxylin and eosin staining and immunohistochemistry (IHC) against multiple biomarkers, including various programmed death ligand 1 (PD‐L1) clones. Next‐generation sequencing was performed on 13 specimens from 5 patients. Results: Postmortem specimens (N = 180) were well preserved from 9 patients with lung cancer. PD‐L1 IHC revealed heterogeneity within and between tumors. An AGK‐BRAF fusion was newly identified in tumor from a donor with a known echinoderm microtubule‐associated protein‐like 4 to anaplastic lymphoma kinase (EML4‐ALK) fusion and history of anaplastic lymphoma kinase (ALK) inhibitor therapy. RNA expression analysis revealed a clonal genetic origin of metastatic cancer cells. Conclusions: Post‐therapy specimens demonstrated PD‐L1 heterogeneity and an acyl glycerol kinase to B‐rapidly accelerated fibrosarcoma (AGK‐BRAF) fusion in a patient with an EML4‐ALK–positive lung adenocarcinoma as a potential resistance mechanism to ALK inhibitor therapy. Rapid tissue donation collection of postmortem tissue from lung cancer patients is a novel approach to cancer research that enables studies of molecular evolution and drug resistance. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Web-based LGBT cultural competency training intervention for oncologists: Pilot study results.

Author

Seay, Julia, Hicks, Amanda, Markham, Merry Jennifer, Schlumbrecht, Matthew, Bowman‐Curci, Meghan, Woodard, Jennifer, Duarte, Luisa F., Quinn, Gwendolyn P., Schabath, Matthew B., and Bowman-Curci, Meghan

Subjects
ONCOLOGISTS, CULTURAL competence, OUTCOME-based education, HEALTH attitudes, PILOT projects, WEB designers, HISPANIC Americans
Abstract

Background: Lesbian, gay, bisexual, and transgender (LGBT) cancer patients experience substantial health disparities, including poorer overall health and lower satisfaction with their cancer care than their heterosexual and cisgender counterparts, which may be due in part to a lack of culturally competent providers. To address these disparities, a web-based LGBT cultural competency training tailored to oncologists was developed by an interdisciplinary team of scientists, LGBT cancer survivors, cultural competency experts, oncologists, a web designer, and an instructional designer.Methods: Oncologists (n = 44) were recruited from 3 academic cancer centers in Florida. Participants were administered the LGBT cultural competency training Curriculum for Oncologists on LGBT populations to Optimize Relevance and Skills (COLORS) and completed pre- and posttraining measures regarding LGBT-related knowledge, attitudes (including general negative attitudes and health care-related attitudes), and clinical practices. After the training, participants completed training acceptability measures.Results: Of the 44 participants, 33 (75%) completed the COLORS training. Participants were 55% non-Hispanic white, 63% male, and had a mean age of 47 years. Participants demonstrated significant improvements in LGBT-related knowledge (t = -4.9, P < .001), attitudes (Z = -3.0, P = .002; t = -2.5, P = .019), and clinical practices (Z = -3.5, P < .001) after completing the COLORS training (Wilcoxon signed rank tests were used for nonnormally distributed variables). Moreover, training acceptability was high, with 82% of participants rating the training as high quality, and 97% being willing to recommend the training to a colleague.Conclusion: The COLORS training is both feasible to administer and acceptable for use with oncologists, and may improve oncologists' LGBT-related knowledge, attitudes, and clinical practices. Larger trials are needed to examine the training's effectiveness in reducing LGBT cancer disparities, as well as its applicability to other types of care providers. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

34. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.

Author

Soto JA, Melo-González F, Gutierrez-Vera C, Schultz BM, Berríos-Rojas RV, Rivera-Pérez D, Piña-Iturbe A, Hoppe-Elsholz G, Duarte LF, Vázquez Y, Moreno-Tapia D, Ríos M, Palacios PA, Garcia-Betancourt R, Santibañez Á, Pacheco GA, Mendez C, Andrade CA, Silva PH, Diethelm-Varela B, Astudillo P, Calvo M, Cárdenas A, González M, Goldsack M, Gutiérrez V, Potin M, Schilling A, Tapia LI, Twele L, Villena R, Grifoni A, Sette A, Weiskopf D, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Retamal-Díaz A, Muñoz-Jofré N, Meng X, Xin Q, Alarcón-Bustamante E, González-Aramundiz JV, Le Corre N, Álvarez-Figueroa MJ, González PA, Abarca K, Perret C, Carreño LJ, Bueno SM, and Kalergis AM

Subjects
Adolescent, Humans, Child, Child, Preschool, Antibodies, Neutralizing, Vaccines, Inactivated, Antibodies, Viral, SARS-CoV-2, COVID-19
Abstract

Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4 + T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD4 + T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD4 + T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials.gov under no. NCT04992260.) IMPORTANCE This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD4 + T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron.

Published
2022
Full Text
View/download PDF

35. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.

Author

Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Kalergis AM, and Bueno SM

Subjects
Adult, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Humans, SARS-CoV-2, T-Lymphocytes, COVID-19 prevention & control, Viral Vaccines
Abstract

CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were significantly reduced at 6 to 8 months after the two doses. Here, we report the effect of a booster dose of CoronaVac on the anti-SARS-CoV-2 immune response generated against the variants of concern (VOCs), Delta and Omicron, in adults participating in a phase III clinical trial in Chile. Volunteers immunized with two doses of CoronaVac in a 4-week interval received a booster dose of the same vaccine between 24 and 30 weeks after the second dose. Neutralization capacities and T cell activation against VOCs Delta and Omicron were assessed 4 weeks after the booster dose. We observed a significant increase in neutralizing antibodies 4 weeks after the booster dose. We also observed a rise in anti-SARS-CoV-2-specific CD4 + T cells over time, and these cells reached a peak 4 weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2-specific T cells induced by the booster showed activity against VOCs Delta and Omicron. Our results show that a booster dose of CoronaVac increases adults' humoral and cellular anti-SARS-CoV-2 immune responses. In addition, immunity induced by a booster dose of CoronaVac is active against VOCs, suggesting adequate protection. IMPORTANCE CoronaVac is an inactivated vaccine against SARS-CoV-2 that has been approved by WHO for emergency use. Phase III clinical trials are in progress in several countries, including China, Brazil, Turkey, and Chile, and have shown safety and immunogenicity after two doses of the vaccine. This report characterizes immune responses induced by two doses of CoronaVac followed by a booster dose 5 months after the second dose in healthy Chilean adults. The data reported here show that a booster dose increased the immune responses against SARS-CoV-2, enhancing levels of neutralizing antibodies against the ancestral strain and VOCs. Similarly, anti-SARS-CoV-2 CD4 + T cell responses were increased following the booster dose. In contrast, levels of gamma interferon secretion and T cell activation against the VOCs Delta and Omicron were not significantly different from those for the ancestral strain. Therefore, a third dose of CoronaVac in a homologous vaccination schedule improves its immunogenicity in healthy volunteers.

Published
2022
Full Text
View/download PDF

36. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.

Author

Schultz BM, Melo-González F, Duarte LF, Gálvez NM, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Vallejos OP, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo M, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Kalergis AM, and Bueno SM

Abstract

Background: CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac ® , but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac ® on the anti-SARS-CoV-2 immune response generated against variants of concern (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile., Methods: Volunteers immunized with two doses of CoronaVac ® in a four-week interval received a booster dose of the same vaccine between twenty-four and thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing antibodies and T cell responses were measured. Neutralization capacities and T cell activation against VOC Delta and Omicron were detected at four weeks after the booster dose., Findings: We observed a significant increase in neutralizing antibodies at four weeks after the booster dose. We also observed an increase in CD4 + T cells numbers over time, reaching a peak at four weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells induced by the booster showed activity against VOC Delta and Omicron., Interpretation: Our results show that a booster dose of CoronaVac ® increases the anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity induced by a booster dose of CoronaVac ® is active against VOC, suggesting an effective protection.

Published
2022
Full Text
View/download PDF

37. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.

Author

Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Dominguez A, Andrade CA, Berrios RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz-Venturelli P, Pérez CM, Potin M, Rojas A, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, and Kalergis AM

Abstract

Background: The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile., Methods: This is a multicenter phase 3 clinical trial. Healthcare workers aged 18 years and older were randomly assigned to receive two doses of CoronaVac or placebo separated by two weeks (0-14). We report preliminary safety results obtained for a subset of 434 participants, and antibody and cell-mediated immunity results obtained in a subset of participants assigned to the immunogenicity arm. The primary and secondary aims of the study include the evaluation of safety parameters and immunogenicity against SARS-CoV-2 after immunization, respectively. This trial is registered at clinicaltrials.gov ( NCT04651790 )., Findings: The recruitment of participants occurred between November 27 th , 2020, until January 9 th , 2021. 434 participants were enrolled, 397 were 18-59 years old, and 37 were ≥60 years old. Of these, 270 were immunized with CoronaVac, and the remaining 164 participants were inoculated with the corresponding placebo. The primary adverse reaction was pain at the injection site, with a higher incidence in the vaccine arm (55.6%) than in the placebo arm (40.0%). Moreover, the incidence of pain at the injection site in the 18-59 years old group was 58.4% as compared to 32.0% in the ≥60 years old group. The seroconversion rate for specific anti-S1-RBD IgG was 47.8% for the 18-59 years old group 14 days post immunization (p.i.) and 95.6% 28 and 42 days p.i. For the ≥60 years old group, the seroconversion rate was 18.1%, 100%, and 87.5% at 14, 28, and 42 days p.i., respectively. Importantly, we observed a 95.7% seroconversion rate in neutralizing antibodies for the 18-59 years old group 28 and 42 days p.i. The ≥60 years old group exhibited seroconversion rates of 90.0% and 100% at 28 and 42 days p.i. Interestingly, we did not observe a significant seroconversion rate of anti-N-SARS-CoV-2 IgG for the 18-59 years old group. For the participants ≥60 years old, a modest rate of seroconversion at 42 days p.i. was observed (37.5%). We observed a significant induction of a T cell response characterized by the secretion of IFN-γ upon stimulation with Mega Pools of peptides derived from SARS-CoV-2 proteins. No significant differences between the two age groups were observed for cell-mediated immunity., Interpretation: Immunization with CoronaVac in a 0-14 schedule in adults of 18 years and older in the Chilean population is safe and induces specific IgG production against the S1-RBD with neutralizing capacity, as well as the activation of T cells secreting IFN-γ, upon recognition of SARS-CoV-2 antigens., Funding: Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results